Enliven Therapeutics Prices $334M Public Offering at $37.50, Significantly Exceeding Initial Target
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (4.3× avg).
Summary
Enliven Therapeutics priced its public offering of 8.9 million shares at $37.50 each, raising approximately $333.75 million. This capital raise is substantially higher than the $250 million initially proposed yesterday. The offering follows the company's recent announcement of strong Phase 1 data for its lead drug ELVN-001 and FDA agreement on Phase 2/3. While the capital infusion significantly extends the company's cash runway, the offering is highly dilutive and priced below the current market price, likely creating downward pressure on the stock.
At the time of this announcement, ELVN was trading at $39.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $14.79 to $48.53. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.